Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Noteable you seem very knowledgeable
View:
Post by Davepark5 on Dec 07, 2022 10:26am

Noteable you seem very knowledgeable

about this stock.  Why is it getting hit so hard after seemingly good news?   typically stocks rise strongly with fast track approval?  not following why this stock continues to tank
Comment by lonc17 on Dec 07, 2022 10:31am
The company has a legal obigation to issue a press release after disclosing material news at SABC. Good or bad, the news is material.   If it was good news, the press release would have been bright and early this morning.  I'm surprised the stock is not down 25%.
Comment by SundayMovies on Dec 07, 2022 10:36am
Ionc17,  I disagree. You don't go to conference with two negative posters. If the news is bad, you just do a press release saying we failed, we tried, we love you, please love us still some time. I think news will be after hours.  I don't care about AWARE-1. It's the Adlai one I care about because of the PR and possible licensing money that goes with it.
Comment by Quentin30 on Dec 07, 2022 10:38am
well perhaps you should care about AWARE-1.. our CEO stated back in 2018, that all Roche needed to pull the trigger (on a deal) was AWARE-1 results.. yup, that worked out well.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities